Dtsch Med Wochenschr 2014; 139(S 01): S27-S30
DOI: 10.1055/s-0033-1359975
Aktuelle Diagnostik & Therapie | Review article
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Gerinnungsmonitoring – praktisches Management

Monitoring of anticoagulation – management in practice
H. Schinzel
1   Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz
,
L. S. Weilemann
1   Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz
› Author Affiliations
Further Information

Publication History

04 November 2013

17 December 2013

Publication Date:
20 January 2014 (online)

 
  • Literatur

  • 1 Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498
  • 2 Bates SM, Weitz JI. Coagulation assays. Circulation 2005; 112: e53-60
  • 3 Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997
  • 4 Frost C, Yu Z, Moore K et al. Apixaban an oral direct factor Xa inhibitor: multiple-dose safety. Pharmacokinetics, and pharmacodynamics in healthy subjects.XXIst ISTH Congress August 2007 (abstract). J Thromb Haemost 2007; 5 (Suppl. 02) P-M 664
  • 5 Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-440
  • 6 Holbrock A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy. American College of Chest Physicans. 9th ed. Chest 2012; 141: 152S-184S
  • 7 Lewandrowski EL, van Cott EM, Gregory K et al. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus. Am J Clin Pathol 2011; 135: 741-748
  • 8 Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843
  • 9 Lewis BE, Wallis DE, Leya F et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856
  • 10 Nieuwenhuis HK, Albada J, Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343
  • 11 Nowak G. The ecarin clotting time, a universal method to quantifiy direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003; 33: 173-183
  • 12 Paolucci F, Frasa H, van Aarle F et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003; 49: 451-460
  • 13 Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-772
  • 14 Samama MM, Contant G, Spiro TE et al. Rivaroxaban antifactor Xa chromogenic assay field trial laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387
  • 15 Schinzel H. Antithrombotika und Fibrinolysetherapie. In Internistische Therapie Wolff. Weihrauch 2012. Kapitel 10, 2013: 289-344
  • 16 Spannagl M, Bauersachs R, Debus ES et al. Patienten unter Therapie mit Dabigatran-Periopertives Management und Interpretation von Gerinnungstesten. Haemostaseologie 2012; 32: 294-305
  • 17 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143